We feel now is a pretty good time to analyse Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) business as it appears the company may be on the cusp of a considerable accomplishment. Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The US$162m market-cap company’s loss lessened since it announced a US$91m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$83m, as it approaches breakeven. Many investors are wondering about the rate at which Tenaya Therapeutics will turn a profit, with the big question being “when will the company breakeven?” We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.
According to the 6 industry analysts covering Tenaya Therapeutics, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2027, before generating positive profits of US$121m in 2028. So, the company is predicted to breakeven approximately 2 years from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 61%, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.
Given this is a high-level overview, we won’t go into details of Tenaya Therapeutics' upcoming projects, though, take into account that generally a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.
View our latest analysis for Tenaya Therapeutics
Before we wrap up, there’s one aspect worth mentioning. Tenaya Therapeutics currently has no debt on its balance sheet, which is rare for a loss-making biotech, which usually has a high level of debt relative to its equity. The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.
Next Steps:
There are too many aspects of Tenaya Therapeutics to cover in one brief article, but the key fundamentals for the company can all be found in one place – Tenaya Therapeutics' company page on Simply Wall St. We've also compiled a list of pertinent factors you should look at:
- Historical Track Record: What has Tenaya Therapeutics' performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Tenaya Therapeutics' board and the CEO’s background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.